Elena Popova, Senior Director of Regulatory Affairs & Healthcare at AIPM, spoke and moderated the session "Digital Transformation of the Industry: How Far Is the Future?"
Popova remarked, "We are witnessing the convergence of industries, where pharmaceuticals, medicine, and technology are merging to create a new landscape for industry. The pharmaceutical industry has evolved from merely producing chemical and biological substances into a provider of comprehensive healthcare solutions”.
During the session, experts discussed their insights into digital project implementation across various stages of a medicinal product's life cycle. They included Meng Chen, Vice President and Head of Biometrics and Data Science at AstraZeneca (China); Michael Pelosi, Head of Quality Assurance and Analytics at Astellas (USA); Igor Sukhomlin, Project Manager at R-Pharm; Artur Kadurin, Head of the AI Center for new medicine development at the AI Institute of Artificial Intelligence; and other industry experts. Topics included:
The role of artificial intelligence and digital twins
The impact of AI on drug registration and quality control regulations
Preparing for AI-driven quality control and good practices
Emerging trends and the future of regulatory frameworks
The Fourth Industrial Revolution and smart factories